A novel, multi-barrier, drug eluting calcium sulfate/biphasic calcium phosphate biodegradable composite bone cement for treatment of experimental MRSA osteomyelitis in rabbit model
Authors:
- 1 October 2016
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 239, 169-181
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Influence of material on the development of device-associated infectionsClinical Microbiology and Infection, 2012
- Treatment of osteomyelitis and repair of bone defect by degradable bioactive borate glass releasing vancomycinJournal of Controlled Release, 2009
- Antibiotic-eluting medical devices for various applicationsJournal of Controlled Release, 2008
- Osteomyelitis: Approach to Diagnosis and TreatmentThe Physician and Sportsmedicine, 2008
- Antibiotics for Local Delivery Systems Cause Skeletal Cell Toxicity In VitroClinical Orthopaedics and Related Research, 2007
- The role of polymethylmethacrylate bone cement in modern orthopaedic surgeryThe Journal of Bone and Joint Surgery. British volume, 2007
- Increased Bone Formation Using Calcium Sulfate-Calcium Phosphate Composite GraftClinical Orthopaedics and Related Research, 2007
- Injectability of calcium phosphate pastesBiomaterials, 2005
- Physiology and Antibiotic Susceptibility of Staphylococcus aureus Small Colony VariantsMicrobial Drug Resistance, 2002
- Experimental Osteomyelitis. I. A Description of the ModelThe Journal of Infectious Diseases, 1970